Literature DB >> 21660969

PKCε promotes cardiac mitochondrial and metabolic adaptation to chronic hypobaric hypoxia by GSK3β inhibition.

Joy McCarthy1, Amanda Lochner, Lionel H Opie, Michael N Sack, M Faadiel Essop.   

Abstract

PKCε is central to cardioprotection. Sub-proteome analysis demonstrated co-localization of activated cardiac PKCε (aPKCε) with metabolic, mitochondrial, and cardioprotective modulators like hypoxia-inducible factor 1α (HIF-1α). aPKCε relocates to the mitochondrion, inactivating glycogen synthase kinase 3β (GSK3β) to modulate glycogen metabolism, hypertrophy and HIF-1α. However, there is no established mechanistic link between PKCε, p-GSK3β and HIF1-α. Here we hypothesized that cardiac-restricted aPKCε improves mitochondrial response to hypobaric hypoxia by altered substrate fuel selection via a GSK3β/HIF-1α-dependent mechanism. aPKCε and wild-type (WT) mice were exposed to 14 days of hypobaric hypoxia (45 kPa, 11% O(2)) and cardiac metabolism, functional parameters, p-GSK3β/HIF-1α expression, mitochondrial function and ultrastructure analyzed versus normoxic controls. Mitochondrial ADP-dependent respiration, ATP production and membrane potential were attenuated in hypoxic WT but maintained in hypoxic aPKCε mitochondria (P < 0.005, n = 8). Electron microscopy revealed a hypoxia-associated increase in mitochondrial number with ultrastructural disarray in WT versus aPKCε hearts. Concordantly, left ventricular work was diminished in hypoxic WT but not aPKCε mice (glucose only perfusions). However, addition of palmitate abrogated this (P < 0.05 vs. WT). aPKCε hearts displayed increased glucose utilization at baseline and with hypoxia. In parallel, p-GSK3β and HIF1-α peptide levels were increased in hypoxic aPKCε hearts versus WT. Our study demonstrates that modest, sustained PKCε activation blunts cardiac pathophysiologic responses usually observed in response to chronic hypoxia. Moreover, we propose that preferential glucose utilization by PKCε hearts is orchestrated by a p-GSK3β/HIF-1α-mediated mechanism, playing a crucial role to sustain contractile function in response to chronic hypobaric hypoxia.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21660969      PMCID: PMC3411281          DOI: 10.1002/jcp.22592

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  66 in total

1.  Overexpression of UCP3 in cultured human muscle lowers mitochondrial membrane potential, raises ATP/ADP ratio, and favors fatty acid vs. glucose oxidation.

Authors:  C García-Martinez; B Sibille; G Solanes; C Darimont; K Macé; F Villarroya; A M Gómez-Foix
Journal:  FASEB J       Date:  2001-07-24       Impact factor: 5.191

2.  TNF alpha is required for hypoxia-mediated right ventricular hypertrophy.

Authors:  R M Smith; J McCarthy; M N Sack
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

3.  Some clinical aspects of life at high altitudes.

Authors:  A HURTADO
Journal:  Ann Intern Med       Date:  1960-08       Impact factor: 25.391

Review 4.  Protein kinase C in cardiac disease and as a potential therapeutic target.

Authors:  Stephen Murphy; William H Frishman
Journal:  Cardiol Rev       Date:  2005 Jan-Feb       Impact factor: 2.644

Review 5.  Development of cardiac sensitivity to oxygen deficiency: comparative and ontogenetic aspects.

Authors:  B Ostadal; I Ostadalova; N S Dhalla
Journal:  Physiol Rev       Date:  1999-07       Impact factor: 37.312

6.  A one-hour minipreparation technique for extraction of DNA-binding proteins from animal tissues.

Authors:  F Deryckere; F Gannon
Journal:  Biotechniques       Date:  1994-03       Impact factor: 1.993

7.  Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFalpha gene.

Authors:  Robert M Smith; Naushaad Suleman; Joy McCarthy; Michael N Sack
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

8.  Flow cytometric analysis of mitochondrial activity in situ: application to acetylceramide-induced mitochondrial swelling and apoptosis.

Authors:  M A Belaud-Rotureau; P Voisin; N Leducq; F Belloc; P Canioni; P Diolez
Journal:  Cytometry       Date:  1998-11-01

9.  Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure.

Authors:  Heiko Bugger; Michael Schwarzer; Dong Chen; Andrea Schrepper; Paulo A Amorim; Maria Schoepe; T Dung Nguyen; Friedrich W Mohr; Oleh Khalimonchuk; Bart C Weimer; Torsten Doenst
Journal:  Cardiovasc Res       Date:  2009-10-19       Impact factor: 10.787

10.  Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1.

Authors:  G L Semenza; B H Jiang; S W Leung; R Passantino; J P Concordet; P Maire; A Giallongo
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

View more
  10 in total

1.  Impaired cardiac ischemic tolerance in spontaneously hypertensive rats is attenuated by adaptation to chronic and acute stress.

Authors:  T Ravingerová; I Bernátová; J Matejíková; V Ledvényiová; M Nemčeková; O Pecháňová; N Tribulová; J Slezák
Journal:  Exp Clin Cardiol       Date:  2011

Review 2.  Cardioprotection by intermittent hypoxia conditioning: evidence, mechanisms, and therapeutic potential.

Authors:  Robert T Mallet; Eugenia B Manukhina; Steven Shea Ruelas; James L Caffrey; H Fred Downey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-04-13       Impact factor: 4.733

3.  Mechanism for reduced pericardial adhesion formation in hypercholesterolemic swine supplemented with alcohol.

Authors:  Antonio D Lassaletta; Louis M Chu; Nassrene Y Elmadhun; Michael P Robich; Zachary G Hoffman; David J Kim; Frank W Sellke
Journal:  Eur J Cardiothorac Surg       Date:  2012-09-18       Impact factor: 4.191

4.  On the pivotal role of PPARα in adaptation of the heart to hypoxia and why fat in the diet increases hypoxic injury.

Authors:  Mark A Cole; Amira H Abd Jamil; Lisa C Heather; Andrew J Murray; Elizabeth R Sutton; Mary Slingo; Liam Sebag-Montefiore; Suat Cheng Tan; Dunja Aksentijević; Ottilie S Gildea; Daniel J Stuckey; Kar Kheng Yeoh; Carolyn A Carr; Rhys D Evans; Ellen Aasum; Christopher J Schofield; Peter J Ratcliffe; Stefan Neubauer; Peter A Robbins; Kieran Clarke
Journal:  FASEB J       Date:  2016-04-21       Impact factor: 5.191

5.  Atorvastatin Attenuates Myocardial Hypertrophy Induced by Chronic Intermittent Hypoxia In Vitro Partly through miR-31/PKCε Pathway.

Authors:  Jie Ren; Wei Liu; Guang-Cai Li; Meng Jin; Zhen-Xi You; Hui-Guo Liu; Yi Hu
Journal:  Curr Med Sci       Date:  2018-06-22

6.  Increased expression of estrogen-related receptor β during adaptation of adult cardiomyocytes to sustained hypoxia.

Authors:  Kathryn F Cunningham; Gyda C Beeson; Craig C Beeson; Paul J McDermott
Journal:  Am J Cardiovasc Dis       Date:  2016-05-18

7.  Effect of regional muscle location but not adiposity on mitochondrial biogenesis-regulating proteins.

Authors:  Jesús Gustavo Ponce-González; Ignacio Ara; Steen Larsen; Borja Guerra; Jose A L Calbet; Jørn Wulff Helge
Journal:  Eur J Appl Physiol       Date:  2015-08-13       Impact factor: 3.078

Review 8.  The involvement of protein kinases in the cardioprotective effect of chronic hypoxia.

Authors:  N V Naryzhnaya; H-J Ma; L N Maslov
Journal:  Physiol Res       Date:  2020-11-02       Impact factor: 1.881

Review 9.  Adaptive Cardiac Metabolism Under Chronic Hypoxia: Mechanism and Clinical Implications.

Authors:  Zhanhao Su; Yiwei Liu; Hao Zhang
Journal:  Front Cell Dev Biol       Date:  2021-02-02

10.  Nox2 Upregulation and p38α MAPK Activation in Right Ventricular Hypertrophy of Rats Exposed to Long-Term Chronic Intermittent Hypobaric Hypoxia.

Authors:  Eduardo Pena; Patricia Siques; Julio Brito; Silvia M Arribas; Rainer Böger; Juliane Hannemann; Fabiola León-Velarde; M Carmen González; M Rosario López; Ángel Luis López de Pablo
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.